Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. (Record no. 26551545)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01866 a2200517 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517122605.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201802s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1179-1926 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/s40262-016-0470-8 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Tout, Mira |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20180221 |
| 245 00 - TITLE STATEMENT | |
| Title | Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Clinical pharmacokinetics |
| Date of publication, distribution, etc. | 06 2017 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 635-647 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antigens, CD20 |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | blood |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | B-Lymphocytes |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Body Surface Area |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Genotype |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leukemia, Lymphocytic, Chronic, B-Cell |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Lymphocyte Count |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Models, Biological |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Polymorphism, Genetic |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Receptors, IgG |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Rituximab |
| General subdivision | blood |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gagez, Anne-Laure |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leprêtre, Stéphane |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gouilleux-Gruart, Valérie |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Azzopardi, Nicolas |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Delmer, Alain |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mercier, Mélanie |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ysebaert, Loïc |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Laribi, Kamel |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gonzalez, Hugo |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Paintaud, Gilles |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cartron, Guillaume |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ternant, David |
| 773 0# - HOST ITEM ENTRY | |
| Title | Clinical pharmacokinetics |
| Related parts | vol. 56 |
| -- | no. 6 |
| -- | p. 635-647 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1007/s40262-016-0470-8">https://doi.org/10.1007/s40262-016-0470-8</a> |
| Public note | Available from publisher's website |
No items available.